Highlights

  • Star Combo Pharma (ASX:S66) has declared a final Dividend of AUD 0.003 per share.
  • The dividend carries an annual Yield of 2.14% and is 100% franked.
  • The shares are scheduled to trade ex-dividend on 13 October 2026, with payment due on 30 October 2026.
  • Contract flow, export Demand and Earnings consistency remain important factors for future distributions.

Star Combo Pharma (ASX:S66) is a small Australian manufacturer of health supplements, vitamins and nutraceutical products, and it is returning cash to shareholders through a fully franked final dividend of AUD 0.003 per share. The shares are scheduled to trade ex-dividend on 13 October 2026, with the Record Date set for 14 October 2026 and payment due on 30 October 2026. The dividend carries an annual yield of 2.14% and is 100% franked, adding an income component to a speculative microcap Investment story.

Dividend in focus

Star Combo Pharma's (ASX:S66) final dividend amounts to AUD 0.003 per share and is fully franked. The annual yield stands at 2.14%, providing a modest income component alongside exposure to the company's nutraceutical Manufacturing and health-products operations.

The ex-dividend date is 13 October 2026, followed by the record date on 14 October 2026. Eligible shareholders are scheduled to receive the payment on 30 October 2026. The 100% franking level may enhance the effective value of the distribution for eligible Australian shareholders able to utilise franking credits.

What is driving the business?

Star Combo manufactures and markets vitamins, supplements and related health products, with contract-manufacturing capability and its own brands. The company has historically pursued export opportunities, including into Asian markets, alongside domestic sales.

Performance depends on order flow from Brand customers, its ability to win and retain manufacturing contracts, and consumer demand for supplements. As a small player, it competes against much larger nutraceutical manufacturers, and its results can swing materially on a handful of contracts or export shipments, making earnings less predictable than at larger peers.

Why income investors may be watching

For income-focused investors, Star Combo Pharma (ASX:S66) stands out because fully franked dividends are less common among microcap companies. The 2.14% annual yield adds an income element while the 100% franking may improve the effective value of the distribution for eligible Australian shareholders.

However, the investment case depends substantially on the consistency of earnings and cash generation. Investors may therefore want to focus on whether the company can maintain profitable operations and sufficient financial flexibility to support future distributions.

Risks

Microcaps like Star Combo carry elevated risks, including thin trading liquidity, higher share-price volatility, customer concentration and sensitivity to a small number of contracts or export markets. A lost contract, regulatory change in a key market or softer supplement demand could quickly affect earnings and cash generation.

Future Shareholder distributions remain discretionary and could be reduced or suspended if operating conditions weaken. Limited scale and concentration also make earnings more volatile than those of larger diversified companies.

Investor takeaway

Star Combo Pharma's fully franked final dividend of AUD 0.003 per share, payable on 30 October 2026, carries an annual yield of 2.14%. With 100% franking, the distribution adds an income component to a microcap health-products business. Investors may want to monitor contract wins, export demand, profitability and cash generation when assessing the sustainability of future distributions.